Multicenter, Single-Blind, Randomized Controlled Study of the Efficacy and Safety of Favipiravir and Nafamostat Mesilate in Patients with COVID-19 Pneumonia Mahoko Ikeda , Shu Okugawa , Kosuke Kashiwabara , Takashi Moritoyo , Yoshiaki Kanno , Daisuke Jubishi , Hideki Hashimoto , Koh Okamoto , Kenji Tsushima , Yasuki Uchida , Takahiro Mitsumura , Hidetoshi Igari , Takeya Tsutsumi , Hideki Araoka , Kazuhiro Yatera , Yoshihiro Yamamoto , Yuki Nakamura , Amato Otani , Marie Yamashita , Yuji Wakimoto , Takayuki Shinohara , Maho Adachi-Katayama , Tatsunori Oyabu , Aoi Kanematsu , Sohei Harada , Yuichiro Takeshita , Yasutaka Nakano , Yasunari Miyazaki , Seiichiro Sakao , Makoto Saito , Sho Ogura , Kei Yamasaki , Hitoshi Kawasuji , Osamu Hataji , Jun-Ichiro Inoue , Yasuyuki Seto , Kyoji Moriya INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES（2023）
Key words
COVID-19, SARS-CoV-2, Pneumonia, Nafamostat mesilate, Favipiravir
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
